Basilea Completes Recruitment for Phase III AntiFungal Trial
By Catherine Shaffer
Staff Writer
Staff Writer
Saturday, December 15, 2012
Basilea Pharmaceutica AG completed recruiting patients for a Phase III pivotal trial of its antifungal agent, isavuconazole. With partner Astellas Pharma Inc., Basilea is studying safety and efficacy of once-daily isavuconazole compared to twice-daily voriconazole for up to 84 days of treatment in infections caused by Aspergillus or other filamentous fungi.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.